Classical Hodgkin lymphoma (HL) is often cured after modern first line regimen but relapsed or refractory (R/R) diseases remain a therapeutical challenge that has been addressed by little randomized clinical trials. Several combinations of brentuximab-vedotin ... ...

请注册登录后继续浏览